We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Erba Mannheim Acquires Maxmat for Diagnostics Analyzers and Advanced Development

By LabMedica International staff writers
Posted on 25 Oct 2015
Print article
Through its Czech subsidiary Erba Lachema, Erba Mannheim (Mannheim, Germany) has expanded its portfolio by acquiring Maxmat SA, France, a company emphasizing development and manufacturing of medical laboratory devices based on original patented technologies.

On September 21, 2015, Erba Mannheim successfully completed its acquisition of Maxmat, whose blood analyzers are used in clinical laboratories in Western Europe, the USA, and other countries. Maxmat SA France has been renamed to Erba Diagnostics France SARL (Montpellie, France). Erba Diagnostics France will benefit the entire Erba group with its capabilities and knowhow in the field of design and development of analyzers that perform multiple functions in a laboratory spanning different segments of biochemistry, hemostasis, and immunology. Among its product-line is a revolutionary multi-analyzer that can conduct hundreds of different biochemistry, coagulation, and immunology tests on a sample.

Jaroslav Rehurek, Managing Director of Erba Lachema, said: “For us, Maxmat represents a great potential in the area of development of medical devices, and therefore it is supposed to contribute to additional growth of our company. Moreover, we are sure that its analyzers will soon find customers in our markets. Furthermore, the acquisition offers a highly favorable synergy with the current portfolio of our company.”

The acquisition will help shrink development timelines for new advanced technologies and to fulfill the needs of diagnostic laboratories. Erba Diagnostics France (formerly Maxmat SA) will also improve the group’s presence in France and French-speaking North African countries.

Mr. Suresh Vazirani, Chairman and Managing Director of Erba’s Transasia Bio-Medicals Ltd, stated, “We are excited about the new opportunities that are offered by this strategic acquisition. This acquisition will strengthen the group’s plans to emerge as a global leader in IVD.” Erba Group and Erba Diagnostics France (formerly Maxmat SA) have drawn up growth plans based on achieving economies of scale, widening product offering, creating synergy through intra-group coordination, and strengthening after-sales service support and distribution network.

Related Links:

Erba Mannheim
Erba Diagnostics France



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.